Slide 1: Corporate Overview September 2021
@ Processa Pharmaceuticals Corporate Overview September 2021
Slide 2: Disclaimer: Forward Looking Statements
Disclaimer: Forward Looking Statements The following summary is provided for informational purposes only and does not constitute an offer or solicitation to acquire interests in the investment or any related or associated company. The information contained here is general in nature and is not intend
Slide 3: Processa Highlights
Processa Highlights >» Development Company Focused on Improving QOL or Survival of patients + Agnostic to the indication as long as the drug treats patients with an unmet medical need condition + Present programs represent 5 different U.S. markets with potential sales of $500 M to $1.5 B for each dr
Slide 4: Processa Capital Structure and Financial Highlights
Processa Capital Structure and Financial Highlights >» PCSA price on September 16, 2021 was $7.84 >» Market Cap on September 16, 2021 was approximately $122 million > Cash on hand on June 30,2021 was $20.8 million which provides a cash runway into late 2023. > Overhead Cash Burn, including salaries
Slide 5: Processa's Risk Abated Approach and Criteria for Drug Selection
Processa’s Risk Abated Approach and Criteria for Drug Selection Experience in Adding Value to Companies: > 30 FDA Approvals & Regulatory Science Contracts from FDA os DEVELOP NOT DISCOVER .—) REGULATORY SCIENCE PLATFORM e ~—. Unmet Medical Need + Efficacy Evidence + Regulatory Science Capital Effici
Slide 6: Processa Pipeline - Five Drugs Each with $1B Market Opportunity
Processa Pipeline - Five Drugs Each with $1B Market Opportunity Multiple High Value Milestones 2021-2022, 4 Phase 3 Trials Initiated 2023-2025, 4 NDAs 2025 - 2028 Drug Disease Target | Preclin | Phase | Phase | Phase Status 2021-2022 Milestones 2023 - 2028 1 3 Milestones PCSs499 Ulcerative 3 Patient
Slide 7: Pipeline Review Based on Timeline of 2021-2022 Milestones
Pipeline Review Based on Timeline of 2021 — 2022 Milestones
Slide 8: 4Q'21 - PCS6422 Interim Analysis with MTD Determined in 2H'22
4Q’21 - PCS6422 Interim Analysis with MTD Determined in 2H’22 PCS6422 Chemotherapy Modifier of Capecitabine (Xeloda®) Irreversibly Inhibiting DPD Enzyme Capecitabine Converts to 5-FU in the body Capecitabine (Xeloda®) + ~ 20% of 5-FU Metabolizes to Molecules with Anti- Tumor Activity and side effect
Slide 9: PCS6422 + Capecitabine Combination Different than Capecitabine
PCS6422 + Capecitabine Combination Different than Capecitabine v Response Rate v Survival Time v HFS Rate &/or Severity v % Treatment Resist. Pts (BB Process Pharmaceuticals > Economic Value: Initial Markets 6422 + Capecitabine combination potential 1% line therapy for a number of cancers (e.g., met
Slide 10: Unmet Medical Need and Evidence of Clinical Benefit
Unmet Medical Need and Evidence of Clinical Benefit > Safety Differentiation of 6422+Capecitabine vs Existing Cancer Chemotherapy 50-70% of capecitabine patients have adverse events from FBAL resulting in decreasing capecitabine dose or stopping chemotherapy Clinical trial of the 6422 + capecitabine
Slide 11: Unmet Medical Need, Evidence of Clinical Benefit, Regulatory Science Platform
Unmet Medical Need, Evidence of Clinical Benefit, Regulatory Science Platform > Efficacy Differentiation of 6422+Capecitabine vs Existing Cancer Chemotherapy + ~30% of patients do not respond at all to capecitabine and ~30% improve CepecitabinelEificacwlnges Hi Lower Dose of 6422 Administered Hours
Slide 12: PCS6422 Chemotherapy Modifier of Capecitabine (Xeloda)
PCS6422 Chemotherapy Modifier of Capecitabine (Xeloda®) > Present Phase 1B Trial to Determine Appropriate Dosing of 6422 and Capecitabine + General Design: MTD Stage 1 will be a 3+3 cohort capecitabine trial after a single safe dose of 6422; 1 dose 6422, 7d of capecitabine, 7d of no capecitabine; up
Slide 13: 4Q'21 - PCS499 Complete Patients Enrolled for 1H'22 Interim Analysis
i eee 4Q’21 - PCS499 Complete Patients Enrolled for 1H’22 Interim Analysis > First to market for the treatment of Ulcerative Necrobiosis Lipoidica (uNL) > Skin, tissue below the skin becomes necrotic, can last from months to ; : " Severe NL Mild NL years with complications such asinfections, amputat
Slide 14: Ulcerative NL (uNL) Target Population
Ulcerative NL (uNL) Target Population Ulcerative Necrobiosis Lipoidica (uNL) > Economic Value: Initial Markets Max Gross Sales + 75,000 — 185,000 NL patients in U.S. * 22,000 - 55,000 uNL patients in U.S. + Presently no approved treatment and off-labeled ~$1.0B drugs have mixed efficacy/safety resul
Slide 15: Unmet Medical Need, Evidence of Clinical Efficacy
Unmet Medical Need, Evidence of Clinical Efficacy > No FDA approved treatment for uNL or NL, no standard of care, all treatments are inadequate > Drugs have been used off-label with mixed success (e.g., pentoxifylline (PTX)) - side effect profile, limited efficacy > PCS499 is the deuterated analog o
Slide 16: Phase 2A PCS499 Improves Benefit-Risk Profile
Phase 2A PCS499 Improves Benefit-Risk Profile > 1.8 gm/d of 499 has better safety profile than 1.2 gm of PTX in animal tox studies and Phase 1 healthy human volunteer studies > In the Phase 2A study of 10 NL and 2 ulcerative NL patients, all ulcers closed in the 2 ulcerative NL patients, including n
Slide 17: PCS499 FDA Designated Orphan Drug - Ulcerative Necrobiosis Lipoidica
PCS499 FDA Designated Orphan Drug - Ulcerative Necrobiosis Lipoidica (UNL) > Phase 2B to Better Define Variables for Phase 3: General Design: Randomized, double-blind, placebo-controlled trial of 1.8 gm/d of 499 in 20 uNL patients with primary efficacy evaluation at 6 months Objective: To determine
Slide 18: 1H'22 - PCS3117 Biomarker Assay Development Completed
1H’22 - PCS3117 Biomarker Assay Development Completed NH, NH, NH» “SN S | pe | AL | Sy N io) A F es N HO. ‘i O HO O 0. IH IH 1H OH OH RX-3117 Gemcitabine (dFdC) Oral Administration IV Administration Cytidine (Cytosine + Ribose Analog) (Cytosine + F,F-Deoxyribose) (Cytosine + Ribose Ring) > Gemcitabi
Slide 19: PCS3117 Treatment Resistant Gemcitabine Patients
PCS3117 Treatment Resistant Gemcitabine Patients > 55% - 85% of patients are inherently resistant to gemcitabine or acquire resistance + Gemcitabine overall response or disease control rate is 15% to 45% depending on type of cancer and trial + Inherent or acquired resistance caused by v Increase in
Slide 20: Differences Between Gemcitabine vs PCS3117
Differences Between Gemcitabine vs PCS3117 Activation to Cancer Killing Metabolites and Mechanism of Cancer Cell Death Gemcitabine HFac ea ee | dFdCDP COA | |OCTO [nor | bition of S DNA synthesis dFdU->—S—dFdU ——— dFdUMP dFdCTP <0 — Apoptosis =S compeftive =s RRM1 me DNA synthesis == cop = dcop —— a
Slide 21: Target Population: More Likely to Respond to or Activate PCS3117 than Gemcitabine
Target Population: More Likely to Respond to or Activate PCS3117 than Gemcitabine > Treat patients more likely to respond to 3117 than gemcitabine which will include inherent resistant and acquired resistant gemcitabine patients who use UCK2 Expression dCK Expression gemcitabine as 1° line therapy o
Slide 22: Evidence of Clinical Efficacy and Safety in Cancer Patients
Evidence of Clinical Efficacy and Safety in Cancer Patients » PCS3117 monotherapy Phase 2A trial as second or third-line therapy in patients with progressive metastatic pancreatic cancer after 1-5 previous therapies of chemotherapy (93% (40/43) refractory to gemcitabine) + 31% (14 patients) had prog
Slide 23: PCS3117 3-15 Month Development Plan in Pancreatic Cancer
PCS3117 3-15 Month Development Plan in Pancreatic Cancer > Refine and evaluate biomarker assays for 3117 over the next 6-9 months: A number of assays presently exist that could potentially be used Assays need to be evaluated and refined for more routine use as required in a Phase 3 pivotal trial as
Slide 24: 2H'22 - PCS12852 Trial Conduct Completed
2H’22 - PCS12852 Trial Conduct Completed PCS12852 Potent-Selective 5HT4 Agonist for Treatment of Gastroparesis > Target Indication: + Treatment of moderate to sever gastroparesis > Target Claims: + Improves gastric emptying rate and the symptoms associated with moderate to severe gastroparesis (e.g.
Slide 25: PCS12852 Potent-Selective 5HT4 Agonist for Treatment of Gastroparesis
PCS12852 Potent-Selective 5HT4 Agonist for Treatment of Gastroparesis > Differentiation of 12852 from Existing therapy + Present use of approved drugs and off- labelled drugs in gastroparesis is limited by side effects of these drugs + All FDA approved drug products for gastroparesis have active ing
Slide 26: PCS12852 Potent-Selective 5HT4 Agonist for Treatment of Gastroparesis
PCS12852 Potent-Selective 5HT4 Agonist for Treatment of Gastroparesis >» Economic Value: Initial Markets + Prevalence of moderate to severe gastroparesis in U.S. reported to be over 200,000 to > 1,500,000 patients depending on formal diagnosis vs symptom presentation + Present use of approved drugs
Slide 27: Processa Highlights
Processa Highlights >» Development Company Focused on Improving QOL or Survival of patients + Agnostic to the indication as long as the drug treats patients with an unmet medical need condition + Present programs represent 5 different U.S. markets with potential sales of $500 M to $1.5 B for each dr
Slide 28: Summary of Key Clinical Data Obtained over the Next 2-15 Months
Summary of Key Clinical Data Obtained over the Next 2-15 Month Multiple High Value Milestones 2021-2022, 4 Phase 3 Trials Initiated 2023-2025, 4 NDAs 2025 - 2028 Determine and Ci PCS6422 2 Phase 1B PCS499 * Continue Patient Phase 2B Recruitment PCS3117 + Initiate Biomarker Phase 2B Assay Development
Slide 29: Our People Lead to Success
Our People Lead to Success Management Team David Young, PharmD. PhD Chief Executive Officer, Chairman of the Sian Bigora, PharmD. Michael Floyd _ Pati Chief Development Officer Chief Operating Officer Patrick Lin James Stanker, CPA Wendy Guy Chief Business - Strategy Officer Chief Financial Officer